Multiple Sclerosis International Federation 19 May 2009


website | contact us | donate
{{if listFind(vars.channel_names, "MSIF News")}}
{{endif}}
{{if listFind(vars.channel_names, "MSIF News")}}
{{endif}}
{{if listFind(vars.channel_names, "MSIF News")}}

MSIF News
{{endif}}
{{if listFind(vars.channel_names, "People With MS News")}}
{{endif}}
{{if listFind(vars.channel_names, "People With MS News")}}
{{endif}}
{{if listFind(vars.channel_names, "People With MS News")}}

Profile of the Month
{{endif}}
{{if listFind(vars.channel_names, "Research News")}}
{{endif}}
{{if listFind(vars.channel_names, "Research News")}}
{{endif}}
{{if listFind(vars.channel_names, "Research News")}}

Research News
{{endif}}
{{if listFind(vars.channel_names, "MS Society News")}}
{{endif}}
{{if listFind(vars.channel_names, "MS Society News")}}
{{endif}}
{{if listFind(vars.channel_names, "MS Society News")}}

MS News
{{endif}}
{{if listFind(vars.channel_names, "MSIF News")}}
{{endif}}
{{if listFind(vars.channel_names, "People With MS News")}}
{{endif}}
{{if listFind(vars.channel_names, "Research News")}}
{{endif}}
{{if listFind(vars.channel_names, "MS Society News")}}
{{endif}}
 

Making Connections

 

MSIF News

Summaries of new MSIF activities, events, projects, programmes, resources, publications and more.
World MS Day 27 May 2009 - one week to go!

With one week to go until the first World MS Day on 27 May 2009 the number of events set to take place has grown to 170 in 54 countries.

read more

MS in focus now in Arabic

Just a reminder that issue 1 of our biannual magazine MS in focus is now available in Arabic.

read more

   
 

Profile of the Month

Summaries of news, views and achievements from people with MS around the world.
Reni de Boer

Profile of the Month : January 2010

Reni de Boer

Country: Netherlands
Age: 29
Type of MS: relapsing-remitting
Year of Diagnosis: 2004

"I am happy to be acting in MSIF’s awareness raising video for World MS Day and am proud to be playing a part in raising more awareness for the 2 million people worldwide with MS."

العربية English Español Francais Italiano Русский

read more

   
 

Research News

Summaries of all the latest research findings on MS selected by a team based at the Institute of Neurology, London.
Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis

MS has been considered as an inflammatory-demyelinating disease of the central nervous system, mainly affecting the white matter. However, the grey matter involvement has been shown to play an important role as well in this disease. Moreover, the exact mechanisms by which the increase of disability occurs in MS are not yet fully understood. In this study the authors have found that the grey matter damage, studied by means of the MTR, a relatively new technique of MRI, could be more strongly related to long-term disability than the white matter damage.

authors: Fisniku L, Altmann D, Cercignani M, Tozer D, Chard D, Jackson J, Miszkiel K, Schmierer K, Thompson A, Miller D

source: Mult Scler. 2009 May 12

read more

Accumulation of cortical lesions in MS: relation with cognitive impairment

The grey matter involvement in MS has been proven to be important. In this study the authors have studied the behaviour of grey matter lesions over time and their relationship with cognitive function. They concluded that the number of lesions appearing in the cortical grey matter seems to increase over time and, more interestingly, that these cortical lesions are related to cognitive decline.

authors: Roosendaal S, Moraal B, Pouwels P, Vrenken H, Castelijns J, Barkhof F, Geurts J

source: Mult Scler. 2009 May 12

read more

Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis

In MS, a disease characterised by the appearance of inflammatory-demyelinating lesions in the white matter, some abnormalities, generally diffuse and not well-defined, in the brain tissue which does not contain the typical lesions can also be seen with the conventional MRI techniques. The meaning of these diffuse abnormalities is not fully understood. In this article the authors have studied the brains (post-mortem) of people with MS and have looked at these regions containing diffuse abnormalities. They concluded that these regions reflect the chronic loss of myelin and axons. As these regions are likely to be contributing to disability in MS, the authors proposed that these abnormalities could be considered as MRI markers of disease progression.

authors: Seewann A, Vrenken H, van der Valk P, Blezer EL, Knol DL, Castelijns JA, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ

source: Arch Neurol. 2009 May;66(5):601-9

read more

A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis

The diagnosis of MS is based on the demonstration of dissemination in space and time of the inflammatory-demyelinating processes characteristic of MS. Over the recent years the diagnostic procedure has evolved and has been simplified, but still at present is quite complex. While before 2001 at least two relapses were required to diagnose MS, since then, the demonstration that new lesions have appeared on the MRI, by comparing two different scans performed in different moments after the first relapse, was enough to have the diagnosis of MS. The authors of this study have demonstrated that with just a single MRI scan of the brain, even performed very early after the first episode, the diagnosis of MS can be made, when certain features indicating dissemination in space and time are present. The results of this work are very important because they might lead to a simplification of the current diagnostic criteria for MS.

authors: Rovira A, Swanton J, Tintoré M, Huerga E, Barkhof F, Filippi M, Frederiksen JL, Langkilde A, Miszkiel K, Polman C, Rovaris M, Sastre-Garriga J, Miller D, Montalban X

source: Arch Neurol. 2009 May;66(5):587-92

read more

Glatiramer acetate treatment in PPMS: Why males appear to respond favorably

In 2007, a clinical trial of glatiramer acetate (GA, Copaxone®) in primary progressive MS (PPMS) was carried out. Though GA did not turn out to be effective in PPMS, when only the male population was observed, some hints of efficacy of GA were suggested. In this article the authors aimed to investigate whether the effect of GA during the clinical trial could have caused different effects in men and in women. However, the authors finally concluded that GA would seem to have caused the same (not significant) clinical effects in men and women. Then, if some differences between both sexes were observed during the trial, these should be attributed to other incidental clinical factors apart from gender.

authors: Wolinsky JS, Shochat T, Weiss S, Ladkani D; for the PROMiSe Trial Study Group

source: J Neurol Sci. 2009 May 7

read more

   
 

MS News

Summaries of MS news from websites around the world.
Hoping the weather holds - Everest update

source: www.empowermentthroughadventure.com and www.wendybooker.net

The two US women with MS, Wendy Booker and Lori Schneider, who are climbing Everest have started their final summit attempt now that the weather in Nepal has improved.

read more

3rd MS awareness seminar takes place in Jeddah, Saudi Arabia

source: Saudi MS Forum

On 14 May 2009 an MS awareness seminar for those newly diagnosed with MS was held in Jeddah, Saudi Arabia.

read more

Five MS research centres established in Canada

source: MS Society of Canada

The MS Society of Canada have announced the establishment of five research and training centres involving more than 100 established scientists and 250 trainees.

read more

EMSP annual conference takes place in Brussels, 13-15 May 2009

source: European MS Platform

120 people from 27 countries attended the European MS Platform’s (EMSP’s) annual conference, on 13-15 May 2009.

read more

40 days, 3,500 miles, more than US$450,000 raised – one man’s journey toward a world free of MS

source: US National MS Society

World MS Day supporter Phil Keoghan has raised more than US$450,000 for the US National MS Society.

read more

New MS drugs growing in popularity but are they increasing the risk of cancer?

source: UK MS Trust

In the first study of its kind, researchers from Canada are examining whether beta-interferon, widely used to treat MS, increases the risk of cancer for people with MS.

read more

 

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

 Click here to learn more about the work of the Making Connections sponsor.